Phosphoinositide 3-kinase δ inhibitor as a novel therapeutic agent in asthma

Respirology

Volumn 13, Issue 6, 2008, Pages 764-771

  Park, Seoung J ^a   Min, Kyung H ^a   Lee, Yong C ^a  

^a Chonbuk National University Medical School   (South Korea)

Author keywords

1 phosphoinositide 3 kinase; Asthma; Inflammation; Lung

Indexed keywords

2 MORPHOLINO 8 PHENYLCHROMONE; CORTICOSTEROID; ISOENZYME; PHOSPHATIDYLINOSITOL 3 KINASE; PHOSPHATIDYLINOSITOL 3 KINASE DELTA; PHOSPHATIDYLINOSITOL 3 KINASE DELTA INHIBITOR; PHOSPHATIDYLINOSITOL 3 KINASE INHIBITOR; UNCLASSIFIED DRUG; WORTMANNIN;

ANTIGEN EXPRESSION; ASTHMA; BRONCHUS HYPERREACTIVITY; CELL ACTIVATION; CELL FUNCTION; CYTOKINE PRODUCTION; ENZYME SUBUNIT; HUMAN; IMMUNOCOMPETENT CELL; INFLAMMATION; INFLAMMATORY CELL; NONHUMAN; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVIEW; SIGNAL TRANSDUCTION;

1-PHOSPHATIDYLINOSITOL 3-KINASE; ASTHMA; HUMANS; PROTEIN ISOFORMS; SIGNAL TRANSDUCTION; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 51349091512     PISSN: 13237799     EISSN: 14401843     Source Type: Journal    
DOI: 10.1111/j.1440-1843.2008.01369.x     Document Type: Review

References (79)

1. Global Initiative for Asthma (GINA). Global Strategy for Asthma Management and Prevention. 2007 Accessed 15 January 2008.] Available from URL: http://www.ginasthma.com.
2. Whitman M, Downes CP, Keeler M, Keller T, Cantley L. Type I phosphatidylinositol kinase makes a novel inositol phospholipid, phosphatidylinositol-3-phosphate. Nature 1988 332 : 644 6.
3. Ward SG, Finan P. Isoform-specific phosphoinositide 3-kinase inhibitors as therapeutic agents. Curr. Opin. Pharmacol. 2003 3 : 426 34.
4. Hennessy BT, Smith DL, Ram PT, Lu Y, Mills GB. Exploiting the PI3K/AKT pathway for cancer drug discovery. Nat. Rev. Drug Discov. 2005 4 : 988 1004.
5. Vanhaesebroeck B, Ali K, Bilancio A, Geering B, Foukas LC. Signalling by PI3K isoforms: insights from gene-targeted mice. Trends Biochem. Sci. 2005 30 : 194 204.
6. Cantley LC. The phosphoinositide 3-kinase pathway. Science 2002 296 : 1655 7.
7. Foster FM, Traer CJ, Abraham SM, Fry MJ. The phosphoinositide (PI) 3-kinase family. J. Cell Sci. 2003 116 : 3037 40.
8. Lee KS, Lee HK, Hayflick JS, Lee YC, Puri KD. Inhibition of phosphoinositide 3-kinase delta attenuates allergic airway inflammation and hyperresponsiveness in murine asthma model. FASEB J. 2006 20 : 455 65.
9. Lee KS, Park SJ, Kim SR, Min KH, Jin SM et al. Phosphoinositide 3-kinase-delta inhibitor reduces vascular permeability in a murine model of asthma. J. Allergy Clin. Immunol. 2006 118 : 403 9.
10. Fruman DA, Cantley LC. Phosphoinositide 3-kinase in immunological systems. Semin. Immunol. 2002 14 : 7 18.
11. Koyasu S. The role of PI3K in immune cells. Nat. Immunol. 2003 4 : 313 19.
12. Gadina M, Sudarshan C, Visconti R, Zhou YJ, Gu H et al. The docking molecule gab2 is induced by lymphocyte activation and is involved in signaling by interleukin-2 and interleukin-15 but not other common gamma chain-using cytokines. J. Biol. Chem. 2000 275 : 26959 66.
13. Lazaar AL, Panettieri RA Jr. Airway smooth muscle: a modulator of airway remodeling in asthma. J. Allergy Clin. Immunol. 2005 116 : 488 95.
14. Dhand R, Hara K, Hiles I, Bax B, Gout I et al. PI 3-kinase: structural and functional analysis of intersubunit interactions. EMBO J. 1994 13 : 511 21.
15. Voigt P, Dorner MB, Schaefer M. Characterization of p87PIKAP, a novel regulatory subunit of phosphoinositide 3-kinase gamma that is highly expressed in heart and interacts with PDE3B. J. Biol. Chem. 2006 281 : 9977 86.
16. Stephens LR, Eguinoa A, Erdjument-Bromage H, Lui M, Cooke F et al. The G beta gamma sensitivity of a PI3K is dependent upon a tightly associated adaptor, p101. Cell 1997 89 : 105 14.
17. Suire S, Coadwell J, Ferguson GJ, Davidson K, Hawkins P et al. p84, a new G beta gamma-activated regulatory subunit of the type IB phosphoinositide 3-kinase p110gamma. Curr. Biol. 2005 15 : 566 70.
18. Leopoldt D, Hanck T, Exner T, Maier U, Wetzker R et al. Gbetagamma stimulates phosphoinositide 3-kinase-gamma by direct interaction with two domains of the catalytic p110 subunit. J. Biol. Chem. 1998 273 : 7024 9.
19. Stoyanov B, Volinia S, Hanck T, Rubio I, Loubtchenkov M et al. Cloning and characterization of a G protein-activated human phosphoinositide-3 kinase. Science 1995 269 : 690 3.
20. Suire S, Condliffe AM, Ferguson GJ, Ellson CD, Guillou H et al. Gbetagammas and the Ras binding domain of p110gamma are both important regulators of PI(3)Kgamma signalling in neutrophils. Nat. Cell Biol. 2006 8 : 1303 9.
21. Ito K, Caramori G, Adcock IM. Therapeutic potential of phosphatidylinositol 3-kinase inhibitors in inflammatory respiratory disease. J. Pharmacol. Exp. Ther. 2007 321 : 1 8.
22. Wurmser AE, Gary JD, Emr SD. Phosphoinositide 3-kinases and their FYVE domain-containing effectors as regulators of vacuolar/lysosomal membrane trafficking pathways. J. Biol. Chem. 1999 274 : 9129 32.
23. Vieira OV, Botelho RJ, Rameh L, Brachmann SM, Matsuo T et al. Distinct roles of class I and class III phosphatidylinositol 3-kinases in phagosome formation and maturation. J. Cell Biol. 2001 155 : 19 25.
24. Roggo L, Bernard V, Kovacs AL, Rose AM, Savoy F et al. Membrane transport in Caenorhabditis elegans: an essential role for VPS34 at the nuclear membrane. EMBO J. 2002 21 : 1673 83.
25. Fukao T, Tanabe M, Terauchi Y, Ota T, Matsuda S et al. PI3K-mediated negative feedback regulation of IL-12 production in DCs. Nat. Immunol. 2002 3 : 875 81.
26. Fukao T, Yamada T, Tanabe M, Terauchi Y, Ota T et al. Selective loss of gastrointestinal mast cells and impaired immunity in PI3K-deficient mice. Nat. Immunol. 2002 3 : 295 304.
27. Palframan RT, Collins PD, Severs NJ, Rothery S, Williams TJ et al. Mechanisms of acute eosinophil mobilization from the bone marrow stimulated by interleukin 5: the role of specific adhesion molecules and phosphatidylinositol 3-kinase. J. Exp. Med. 1998 188 : 1621 32.
28. Dunzendorfer S, Meierhofer C, Wiedermann CJ. Signaling in neuropeptide-induced migration of human eosinophils. J. Leukoc. Biol. 1998 64 : 828 34.
29. Krymskaya VP, Penn RB, Orsini MJ, Scott PH, Plevin RJ et al. Phosphatidylinositol 3-kinase mediates mitogen-induced human airway smooth muscle cell proliferation. Am. J. Physiol. 1999 277 : L65 78.
30. Kwak YG, Song CH, Yi HK, Hwang PH, Kim JS et al. Involvement of PTEN in airway hyperresponsiveness and inflammation in bronchial asthma. J. Clin. Invest. 2003 111 : 1083 92.
31. Medina-Tato DA, Ward SG, Watson ML. Phosphoinositide 3-kinase signalling in lung disease: leucocytes and beyond. Immunology 2007 121 : 448 61.
32. Lee KS, Kim SR, Park SJ, Lee HK, Park HS et al. Phosphatase and tensin homolog deleted on chromosome 10 (PTEN) reduces vascular endothelial growth factor expression in allergen-induced airway inflammation. Mol. Pharmacol. 2006 69 : 1829 39.
33. Duan W, Aguinaldo Datiles AM, Leung BP, Vlahos CJ, Wong WS. An anti-inflammatory role for a phosphoinositide 3-kinase inhibitor LY294002 in a mouse asthma model. Int. Immunopharmacol. 2005 5 : 495 502.
34. Gosens R, Bromhaar MM, Tonkes A, Schaafsma D, Zaagsma J et al. Muscarinic M3 receptor-dependent regulation of airway smooth muscle contractile phenotype. Br. J. Pharmacol. 2004 141 : 943 50.
35. Day RM, Lee YH, Park AM, Suzuki YJ. Retinoic acid inhibits airway smooth muscle cell migration. Am. J. Respir. Cell Mol. Biol. 2006 34 : 695 703.
36. Halayko AJ, Kartha S, Stelmack GL, McConville J, Tam J et al. Phosphatidylinositol-3 kinase/mammalian target of rapamycin/p70S6K regulates contractile protein accumulation in airway myocyte differentiation. Am. J. Respir. Cell Mol. Biol. 2004 31 : 266 75.
37. Finan PM, Thomas MJ. PI 3-kinase inhibition: a therapeutic target for respiratory disease. Biochem. Soc. Trans. 2004 32 : 378 82.
38. Ward S, Sotsios Y, Dowden J, Bruce I, Finan P. Therapeutic potential of phosphoinositide 3-kinase inhibitors. Chem. Biol. 2003 10 : 207 13.
39. Davies SP, Reddy H, Caivano M, Cohen P. Specificity and mechanism of action of some commonly used protein kinase inhibitors. Biochem. J. 2000 351 : 95 105.
40. Knight ZA, Chiang GG, Alaimo PJ, Kenski DM, Ho CB et al. Isoform-specific phosphoinositide 3-kinase inhibitors from an arylmorpholine scaffold. Bioorg. Med. Chem. 2004 12 : 4749 59.
41. Liu Y, Shreder KR, Gai W, Corral S, Ferris DK et al. Wortmannin, a widely used phosphoinositide 3-kinase inhibitor, also potently inhibits mammalian polo-like kinase. Chem. Biol. 2005 12 : 99 107.
42. Bi L, Okabe I, Bernard DJ, Wynshaw-Boris A, Nussbaum RL. Proliferative defect and embryonic lethality in mice homozygous for a deletion in the p110alpha subunit of phosphoinositide 3-kinase. J. Biol. Chem. 1999 274 : 10963 8.
43. Bi L, Okabe I, Bernard DJ, Nussbaum RL. Early embryonic lethality in mice deficient in the p110beta catalytic subunit of PI 3-kinase. Mamm. Genome. 2002 13 : 169 72.
44. Chantry D, Vojtek A, Kashishian A, Holtzman DA, Wood C et al. p110delta, a novel phosphatidylinositol 3-kinase catalytic subunit that associates with p85 and is expressed predominantly in leukocytes. J. Biol. Chem. 1997 272 : 19236 41.
45. Al-Alwan MM, Okkenhaug K, Vanhaesebroeck B, Hayflick JS, Marshall AJ. Requirement for phosphoinositide 3-kinase p110delta signaling in B cell antigen receptor-mediated antigen presentation. J. Immunol. 2007 178 : 2328 35.
46. Wohlleben G, Erb KJ. Immune stimulatory strategies for the prevention and treatment of asthma. Curr. Pharm. Des. 2006 12 : 3281 92.
47. Heijink IH, Van Oosterhout AJ. Targeting T cells for asthma. Curr. Opin. Pharmacol. 2005 5 : 227 31.
48. Larché M. Regulatory T cells in allergy and asthma. Chest 2007 132 : 1007 14.
49. Okkenhaug K, Bilancio A, Farjot G, Priddle H, Sancho S et al. Impaired B and T cell antigen receptor signaling in p110delta PI 3-kinase mutant mice. Science 2002 297 : 1031 4.
50. Clayton E, Bardi G, Bell SE, Chantry D, Downes CP et al. A crucial role for the p110delta subunit of phosphatidylinositol 3-kinase in B cell development and activation. J. Exp. Med. 2002 196 : 753 63.
51. Puri KD, Doggett TA, Douangpanya J, Hou Y, Tino WT et al. Mechanisms and implications of phosphoinositide 3-kinase delta in promoting neutrophil trafficking into inflamed tissue. Blood 2004 103 : 3448 56.
52. +CD25+Foxp3+ regulatory T cells. J. Immunol. 2006 177 : 6598 602.
53. Sadhu C, Dick K, Tino WT, Staunton DE. Selective role of PI3K delta in neutrophil inflammatory responses. Biochem. Biophys. Res. Commun. 2003 308 : 764 9.
54. Sadhu C, Masinovsky B, Dick K, Sowell CG, Staunton DE. Essential role of phosphoinositide 3-kinase delta in neutrophil directional movement. J. Immunol. 2003 170 : 2647 54.
55. Puri KD, Doggett TA, Huang CY, Douangpanya J, Hayflick JS et al. The role of endothelial PI3Kgamma activity in neutrophil trafficking. Blood 2005 106 : 150 7.
56. Barnes PJ. New molecular targets for the treatment of neutrophilic diseases. J. Allergy Clin. Immunol. 2007 119 : 1055 62.
57. Jatakanon A, Uasaf C, Maziak W, Lim S, Chung KF et al. Neutrophilic inflammation in severe persistent asthma. Am. J. Respir. Crit. Care Med. 1999 160 : 1532 9.
58. Gibson PG, Simpson JL, Saltos N. Heterogeneity of airway inflammation in persistent asthma: evidence of neutrophilic inflammation and increased sputum interleukin-8. Chest 2001 119 : 1329 36.
59. Simpson JL, Scott R, Boyle MJ, Gibson PG. Inflammatory subtypes in asthma: assessment and identification using induced sputum. Respirology 2006 11 : 54 61.
60. Green RH, Brightling CE, Woltmann G, Parker D, Wardlaw AJ et al. Analysis of induced sputum in adults with asthma: identification of subgroup with isolated sputum neutrophilia and poor response to inhaled corticosteroids. Thorax 2002 57 : 875 9.
61. Chalmers GW, Macleod KJ, Thomson L, Little SA, McSharry C et al. Smoking and airway inflammation in patients with mild asthma. Chest 2001 120 : 1917 22.
62. Fahy JV, Kim KW, Liu J, Boushey HA. Prominent neutrophilic inflammation in sputum from subjects with asthma exacerbation. J. Allergy Clin. Immunol. 1995 95 : 843 52.
63. Knight ZA, Gonzalez B, Feldman ME, Zunder ER, Goldenberg DD et al. A pharmacological map of the PI3-K family defines a role for p110alpha in insulin signaling. Cell 2006 125 : 733 47.
64. Ali K, Bilancio A, Thomas M, Pearce W, Gilfillan AM et al. Essential role for the p110delta phosphoinositide 3-kinase in the allergic response. Nature 2004 431 : 1007 11.
65. Nashed BF, Zhang T, Al-Alwan M, Srinivasan G, Halayko AJ et al. Role of the phosphoinositide 3-kinase p110delta in generation of type 2 cytokine responses and allergic airway inflammation. Eur. J. Immunol. 2007 37 : 416 24.
66. Bousquet J, Jeffery PK, Busse WW, Johnson M, Vignola AM. Asthma. From bronchoconstriction to airways inflammation and remodeling. Am. J. Respir. Crit. Care Med. 2000 161 : 1720 45.
67. Lee YC, Kwak YG, Song CH. Contribution of vascular endothelial growth factor to airway hyperresponsiveness and inflammation in a murine model of toluene diisocyanate-induced asthma. J. Immunol. 2002 168 : 3595 600.
68. Van de Graaf EA, Out TA, Roos CM, Jansen HM. Respiratory membrane permeability and bronchial hyperreactivity in patients with stable asthma. Effects of therapy with inhaled steroids. Am. Rev. Respir. Dis. 1991 143 : 362 8.
69. Lee KS, Kim SR, Park HS, Jin GY, Lee YC. Cysteinyl leukotriene receptor antagonist regulates vascular permeability by reducing vascular endothelial growth factor expression. J. Allergy Clin. Immunol. 2004 114 : 1093 9.
70. Lee CG, Link H, Baluk P, Homer RJ, Chapoval S et al. Vascular endothelial growth factor (VEGF) induces remodeling and enhances TH2-mediated sensitization and inflammation in the lung. Nat. Med. 2004 10 : 1095 103.
71. Thurston G, Rudge JS, Ioffe E, Zhou H, Ross L et al. Angiopoietin-1 protects the adult vasculature against plasma leakage. Nat. Med. 2000 6 : 460 3.
72. Lee YC, Lee HK. Vascular endothelial growth factor in patients with acute asthma. J. Allergy Clin. Immunol. 2001 107 : 1106.
73. Asai K, Kanazawa H, Kamoi H, Shiraishi S, Hirata K et al. Increased levels of vascular endothelial growth factor in induced sputum in asthmatic patients. Clin. Exp. Allergy. 2003 33 : 595 9.
74. Hoshino M, Takahashi M, Aoike N. Gene expression of vascular endothelial growth factor and its receptors and angiogenesis in bronchial asthma. J. Allergy Clin. Immunol. 2001 107 : 1034 8.
75. Wang GL, Semenza GL. Purification and characterization of hypoxia-inducible factor 1. J. Biol. Chem. 1995 270 : 1230 7.
76. 2 homeostasis by hypoxia-inducible factor 1. Annu. Rev. Cell Dev. Biol. 1999 15 : 551 78.
77. Ezeamuzie CI, Sukumaran J, Philips E. Effect of wortmannin on human eosinophil responses in vitro and on bronchial inflammation and airway hyperresponsiveness in Guinea pigs in vivo. Am. J. Respir. Crit. Care Med. 2001 164 : 1633 9.
78. Zhu X, Subbaraman R, Sano H, Jacobs B, Sano A et al. A surrogate method for assessment of beta(2)-integrin-dependent adhesion of human eosinophils to ICAM-1. J. Immunol. Methods 2000 240 : 157 64.
79. Fujio Y, Walsh K. Akt mediates cytoprotection of endothelial cells by vascular endothelial growth factor in an anchorage-dependent manner. J. Biol. Chem. 1999 274 : 16349 54.